We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Nova Biomedical

Nova is a world leader in the development and manufacturing of whole blood, point-of-care and critical care analyzers... read more Featured Products: More products

Download Mobile App




Advanced Instruments Merged Under Nova Biomedical Name

By LabMedica International staff writers
Posted on 27 Oct 2025

Advanced Instruments (Norwood, MA, USA) and Nova Biomedical (Waltham, MA, USA) are now officially doing business under a single, unified brand. More...

This transformation is expected to deliver greater value to customers across the biopharmaceutical and clinical markets. Advanced Instruments has also unveiled a refreshed brand identity and logo across the merged organization, reflecting its forward-looking vision and deep commitment to innovation.

This strategic merger brings together two industry leaders with complementary strengths in analytical instrumentation, R&D, and global customer support. By combining their technologies and expertise, both companies are better positioned to support customer workflows, accelerate biopharmaceutical development, and improve patient care worldwide.

While the Advanced Instruments name will evolve into a product portfolio brand for its osmolality testing solutions, it will remain a symbol of excellence within the Nova Biomedical umbrella. Customers can now see the Nova Biomedical name and new visual identity reflected across the communications, digital assets, and products of Advanced Instruments. This branding update is designed to signal investment by Advanced Instruments in the future and its commitment to staying at the forefront of life science innovation.

Advanced Instruments has affirmed that this is only a branding change with legal entities, operational processes, and customer interactions remaining unchanged. The company’s customers can continue working with their existing sales and service contacts and process orders and inquiries as usual.

"Our shared values—innovation, customer focus, and dedication to quality—are the foundation of this merger," said Byron Selman, President & CEO of Nova Biomedical. "Operating under the Nova Biomedical name allows us to amplify our global presence and continue delivering gold-standard solutions to our customers."

Related Links:
Advanced Instruments
Nova Biomedical


Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Portable Electronic Pipette
Mini 96
New
Gold Member
Hybrid Pipette
SWITCH
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: When assessing the same lung biopsy sample, research shows that only 18% of pathologists will agree on a TCMR diagnosis (Photo courtesy of Thermo Fisher)

Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection

Lung transplant recipients face a significant risk of rejection and often require routine biopsies to monitor graft health, yet assessing the same biopsy sample can be highly inconsistent among pathologists.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.